drugset
Drugs / Afatinib
last change 10 days ago re-read 9 days ago

Afatinib

also known as BIBW2992 · Gilotrif · Afatinib Dimaleate

Small molecule targets EGFR, ERBB2, ERBB3, ERBB4 via inhibition

Developed for
non-small cell lung carcinoma · neoplasm · head and neck squamous cell carcinoma · esophageal squamous cell carcinoma · lung cancer · breast cancer · breast neoplasm · head and neck neoplasm
+51 more · squamous cell carcinoma · refractory malignant neoplasm · cancer · plasma cell myeloma · colorectal neoplasm · esophageal cancer · gastric cancer · gastroesophageal cancer · head and neck cancer · metastatic malignant neoplasm · adenocarcinoma · adult lymphoma · brain cancer · breast carcinoma · gastric neoplasm · glioma · HER2 positive breast carcinoma · metastatic malignant neoplasm in the brain · metastatic neoplasm · urinary bladder carcinoma · acute leukemia of ambiguous lineage · acute lymphoblastic leukemia · adult glioblastoma · central nervous system neoplasm · cholangiocarcinoma · chordoma · clivus chordoma · colorectal cancer · digestive system carcinoma · endometrial serous adenocarcinoma · endometriosis of intestine · Fanconi anemia · gallbladder carcinoma · gastroesophageal adenocarcinoma · glioblastoma · lung adenocarcinoma · lung neoplasm · neoplastic meningitis · neuroepithelial neoplasm · non-small cell squamous lung carcinoma · ovarian endometriosis · pancreatic ductal adenocarcinoma · prostate neoplasm · rhabdomyosarcoma · squamous cell lung carcinoma · triple-negative breast carcinoma · upper aerodigestive tract neoplasm · ureter cancer · urethra cancer · urinary system neoplasm · urothelial carcinoma
Investigated by
Boehringer Ingelheim · National Cancer Institute (NCI) · West China Hospital · National Comprehensive Cancer Network · Peking University · European Organisation for Research and Treatment of Cancer - EORTC
+132 more · Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · National Taiwan University Hospital · The Netherlands Cancer Institute · Vanderbilt-Ingram Cancer Center · Yonsei University · Amgen · AstraZeneca · Bayer · Bristol-Myers Squibb · China Medical University Hospital · Dana-Farber Cancer Institute · Fujian Cancer Hospital · H. Lee Moffitt Cancer Center and Research Institute · Incyte Corporation · Merck Sharp & Dohme LLC · National University Hospital, Singapore · PD Dr. med. Volker Heinemann · Shanghai Chest Hospital · UNICANCER · University College, London · Yale University · AHS Cancer Control Alberta · AIO-Studien-gGmbH · Aiping Zhou · Amsterdam UMC, location VUmc · Baodong Qin · BioGene Pharmaceutical Ltd. · Bioven Europe · Cambridge University Hospitals NHS Foundation Trust · Cancer Research UK · Center Trials & Treatment · Center Trials & Treatment Europe · Centre Leon Berard · Chang Gung Memorial Hospital · Changshu Affiliated Hospital of Soochow University · China Medical University, Taiwan · Chinese Thoracic Oncology Group · Chonnam National University Hospital · Chordoma Foundation · Clovis Oncology - Pharma and · Columbia University · Dutch Cancer Society · ECOG-ACRIN Cancer Research Group · ETOP IBCSG Partners Foundation · Eisai Inc. · Eli Lilly and Company · Exelixis · Fifth Affiliated Hospital, Sun Yat-Sen University · Fondation Hôpital Saint-Joseph · Foundation Medicine · French Cooperative Thoracic Intergroup · GBG Forschungs GmbH · German Cancer Research Center · German Consortium for Translational Cancer Research · GlaxoSmithKline · Groupe Oncologie Radiotherapie Tete et Cou · Guangdong Association of Clinical Trials · Hellenic Cooperative Oncology Group · Huashan Hospital · Instituto Oncológico Dr Rosell · Ipsen · Janssen, LP · Jeeyun Lee · Johannes Gutenberg University Mainz · Jonathan Riess · Kaohsiung Medical University Chung-Ho Memorial Hospital · Lanzhou University Second Hospital · Leiden University Medical Center · M.D. Anderson Cancer Center · MFAR · MFAR Clinical Research S.L. · Medical University of South Carolina · Merck Serono International SA · all 138 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed RET fusion positive cancer 2 milestones
Filed US (FDA) — RET fusion positive cancer 2013-01-15

“the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing” prnewswire.com ↗
Filed EU (EMA) — RET fusion positive cancer —

“recently submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of afatinib as a treatment” prnewswire.com ↗
Approved Indication not stated 2 milestones
Filed US (FDA) Gilotrif non-small cell lung cancer with uncommon EGFR mutations 2017-10-10

“the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).” prnewswire.com ↗
Approved EU (EMA) Giotrif — 2013-09-25 europa.eu ↗

Trials 189 · started per year

today
EU approved 2013
1
4
2
4
5
7
11
9
11
18
13
10
18
12
8
9
5
7
9
5
4
7
6
1
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05432518 Jun 2023 → Jul 2027 expected adult glioblastoma AHS Cancer Control Alberta Recruiting No outcome recorded
Phase 151 trials · 3 missed
Phase 1 NCT06897735 Nov 2025 → May 2026 lung cancer, melanoma, oral cavity cancer Petrov, Andrey Terminated No outcome recorded
Phase 1 NCT06741982 Dec 2024 → Dec 2026 expected head and neck squamous cell carcinoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT06494189 Jul 2024 → Apr 2025 head and neck cancer West China Hospital Completed No outcome recorded
Phase 1 NCT06302621 Apr 2024 → Dec 2027 expected cholangiocarcinoma, metastatic neoplasm Massachusetts General Hospital Recruiting No outcome recorded
Phase 1 NCT05927844 Jun 2023 → Jun 2025 esophageal squamous cell carcinoma Fujian Cancer Hospital Unknown No outcome recorded
Phase 1 NCT05164848 Dec 2021 → Oct 2023 esophageal squamous cell carcinoma Peking University Unknown No outcome recorded
Phase 1 NCT03878524 Apr → Dec 2020 acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 OHSU Knight Cancer Institute Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT04185883 Dec 2019 → Dec 2026 expected cancer Amgen Active not recruiting No outcome recorded
Phase 1 NCT03827070 Mar 2019 → Feb 2023 non-small cell lung carcinoma Center Trials & Treatment Europe Unknown No outcome recorded
Phase 1 NCT03711422 Nov 2018 → Dec 2019 central nervous system neoplasm, neoplastic meningitis, non-small cell lung carcinoma National Cancer Centre, Singapore Terminated No outcome recorded Stop: Enrollment
Phase 1/213 trials
Phase 1/2 NCT06753747 Sep 2025 → Sep 2027 expected esophageal cancer West China Hospital Recruiting No outcome recorded
Phase 1/2 NCT07010120 Jun 2025 → May 2027 expected head and neck squamous cell carcinoma West China Hospital Active not recruiting No outcome recorded
Phase 1/2 NCT06648096 Nov 2024 → Dec 2028 expected Fanconi anemia, head and neck squamous cell carcinoma Sant Pau Research Institute Recruiting No outcome recorded
Phase 1/2 NCT06085755 Sep 2024 → Dec 2025 overdue gastric neoplasm Jeeyun Lee Recruiting No outcome recorded
Phase 1/2 NCT06071013 Feb 2024 → Aug 2026 overdue non-small cell lung carcinoma China Medical University Hospital Recruiting No outcome recorded
Phase 1/2 NCT03481842 Oct 2021 endometriosis of intestine, ovarian endometriosis BioGene Pharmaceutical Ltd. Withdrawn No outcome recorded
Phase 1/2 NCT03785249 Jan 2019 → Dec 2026 expected metastatic malignant neoplasm Mirati Therapeutics Inc. Active not recruiting No outcome recorded
Phase 1/2 NCT03623750 Jul 2018 → Mar 2020 non-small cell lung carcinoma Instituto Oncológico Dr Rosell Completed No outcome recorded
Phase 1/2 NCT02450656 Jun 2015 → May 2019 colorectal neoplasm, non-small cell lung carcinoma, pancreatic neoplasm The Netherlands Cancer Institute Unknown No outcome recorded
Phase 1/2 NCT02372006 Apr 2015 → Aug 2020 neuroepithelial neoplasm, rhabdomyosarcoma Boehringer Ingelheim Completed No outcome recorded
Phase 295 trials · 4 met primary · 7 missed
Phase 2 NCT07040956 Jun 2025 → Jun 2026 head and neck squamous cell carcinoma West China Hospital Completed No outcome recorded
Phase 2 NCT06709859 May 2025 → May 2026 overdue non-small cell lung carcinoma Shandong Public Health Clinical Center Recruiting No outcome recorded
Phase 2 NCT06804850 Jan 2025 → Jun 2026 head and neck cancer West China Hospital Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT06062823 Mar 2024 → Oct 2026 expected non-small cell lung carcinoma National University Hospital, Singapore Recruiting No outcome recorded
Phase 2 NCT05865132 Apr 2023 → Apr 2025 esophageal squamous cell carcinoma Aiping Zhou Unknown No outcome recorded
Phase 2 NCT05818982 Feb 2023 → Feb 2025 esophageal squamous cell carcinoma Peking University Unknown No outcome recorded
Phase 2 NCT05519917 Oct 2022 → Jun 2025 clivus chordoma Huashan Hospital Unknown No outcome recorded
Phase 2 NCT05517330 Sep 2022 → Dec 2023 head and neck squamous cell carcinoma West China Hospital Completed No outcome recorded
Phase 2 NCT05516589 Sep 2022 → Oct 2023 head and neck squamous cell carcinoma West China Hospital Completed No outcome recorded
Phase 2 NCT04410653 Jul 2022 → Oct 2023 — German Cancer Research Center Completed No outcome recorded
Phase 2/32 trials · 1 missed
Phase 2/3 NCT07653451 Jul 2026 → Dec 2027 expected esophageal squamous cell carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2/3 NCT02438722 May 2015 → Sep 2018 non-small cell lung carcinoma SWOG Cancer Research Network Completed Missed primary
Phase 315 trials · 6 met primary · 4 missed
Phase 3 NCT02131155 Jul 2014 → Aug 2016 head and neck neoplasm Boehringer Ingelheim Terminated No outcome recorded
Phase 3 NCT02044380 Mar 2014 → Feb 2016 non-small cell lung carcinoma Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT01953913 Sep 2013 → Jul 2018 non-small cell lung carcinoma Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT01853826 Jul 2013 → Mar 2024 non-small cell lung carcinoma Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT01856478 Jun 2013 → Aug 2018 head and neck neoplasm Boehringer Ingelheim Completed Met primary
Phase 3 NCT01814553 Apr 2013 → Jul 2015 non-small cell lung carcinoma Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT01523587 Mar 2012 → Oct 2013 non-small cell lung carcinoma Boehringer Ingelheim Completed Met primary
Phase 3 NCT01345682 Jan 2012 → Mar 2014 head and neck neoplasm, squamous cell carcinoma Boehringer Ingelheim Completed Met primary
Phase 3 NCT01345669 Oct 2011 → Sep 2016 head and neck neoplasm Boehringer Ingelheim Terminated Missed primary
Phase 3 NCT01427478 Sep 2011 → Nov 2020 head and neck squamous cell carcinoma Centre Leon Berard Completed Missed primary
Phase 46 trials
Phase 4 NCT04814056 Jun 2021 → Sep 2023 non-small cell lung carcinoma Shanghai Chest Hospital Unknown No outcome recorded
Phase 4 NCT04413201 Sep 2020 → Dec 2026 expected non-small cell lung carcinoma Michael Hopp Active not recruiting No outcome recorded
Phase 4 NCT04132102 Nov 2018 → Apr 2021 squamous cell lung carcinoma Shanghai Chest Hospital Unknown No outcome recorded
Phase 4 NCT02695290 Mar → Aug 2016 non-small cell lung carcinoma Boehringer Ingelheim Terminated No outcome recorded
Phase 4 NCT02514174 Aug 2015 → Mar 2019 non-small cell lung carcinoma Boehringer Ingelheim Completed No outcome recorded
Phase 4 NCT02208843 Oct 2014 → May 2017 non-small cell lung carcinoma Boehringer Ingelheim Completed No outcome recorded
Phase not applicable2 trials
— NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
— NCT01074177 Feb 2011 → Mar 2017 RET fusion positive cancer, non-small cell lung carcinoma Massachusetts General Hospital Completed No outcome recorded
Phase not stated4 trials
— NCT01649284 Jul 2012 → Mar 2014 non-small cell lung carcinoma Boehringer Ingelheim Approved for marketing No outcome recorded
— NCT05107193 — cancer Boehringer Ingelheim No longer available No outcome recorded
— NCT01931306 — non-small cell lung carcinoma Boehringer Ingelheim Approved for marketing No outcome recorded
— NCT01209650 — non-small cell lung carcinoma Boehringer Ingelheim Approved for marketing No outcome recorded
Comparator or background therapy10 trials
Phase 1 NCT07271446 Background Sep 2018 → Aug 2019 non-small cell lung carcinoma Precision Biotech Taiwan Corp. Completed No outcome recorded
Phase 1/2 NCT02906163 Background Oct 2016 → Dec 2019 lung cancer SciClone Pharmaceuticals Unknown No outcome recorded
Phase 2 NCT05588609 Background Nov 2022 → Jul 2025 castration-resistant prostate carcinoma Partner Therapeutics, Inc. Terminated No outcome recorded
Phase 2 NCT01746251 Comparator Jan 2013 → Nov 2020 non-small cell lung carcinoma Massachusetts General Hospital Unknown No outcome recorded
Phase 3 NCT07185997 Comparator Dec 2025 → Feb 2029 expected non-small cell lung carcinoma ArriVent BioPharma, Inc. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 28

DateIssuerRelease
2023-04-14 AstraZeneca Results AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗
Combination of T-DXd with the irreversible pan-HER TKI afatinib drives combination benefit in HER2-low gastric and lung tumours
2020-10-13 Boehringer Ingelheim Results IASLC NACLC 2020: Boehringer Ingelheim presents new data for Gilotrif® in metastatic, squamous cell carcinoma of the lung, and in EGFR mutation-positive NSCLC prnewswire.com ↗
Boehringer Ingelheim today announced new data for Gilotrif® (afatinib) which further affirm its activity in squamous cell carcinoma of the lung and, in a separate study, epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).
2020-09-02 Boehringer Ingelheim Results Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer prnewswire.com ↗
Results showed that Asian and Del19-positive patients saw a median OS of 44.8 months (90% CI: 37.0–57.8) and 41.6 months (90% CI: 36.9–45.0) respectively.
2020-08-10 Boehringer Ingelheim Results Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC prnewswire.com ↗
2019-08-05 Boehringer Ingelheim Results Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC prnewswire.com ↗
Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS) of almost four years (45.7 months) in patients with Del19-positive tumors.
2018-10-22 Boehringer Ingelheim Results Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC prnewswire.com ↗
According to the study, the median time on treatment for sequential afatinib and osimertinib was 27.6 months.
2018-01-16 Boehringer Ingelheim Regulatory FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC prnewswire.com ↗
2017-10-10 Boehringer Ingelheim Regulatory FDA grants Priority Review to Gilotrif® for uncommon EGFR mutations in advanced NSCLC prnewswire.com ↗
Boehringer Ingelheim today announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).
2016-10-09 Boehringer Ingelheim Results Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO prnewswire.com ↗
The median survival of patients treated with afatinib was 27.9 months compared to 24.5 months for those receiving gefitinib, without reaching significance.
2016-09-08 Boehringer Ingelheim Results New analysis showed dose adjustment of Gilotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer prnewswire.com ↗
The analysis suggests specific dose reductions, as described in the prescribing information, led to decreases in the incidence and severity of treatment-related adverse events (AEs) in afatinib-treated patients without any apparent compromise in efficacy.
2016-04-15 Boehringer Ingelheim Regulatory FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung prnewswire.com ↗
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy.
2016-04-13 Boehringer Ingelheim Results Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology prnewswire.com ↗
Results from the LUX-Lung 7 trial showed that afatinib significantly reduced the risk of lung cancer progression by 27% versus gefitinib.

All press releases naming this drug 35 releases

DateIssuerRelease

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 204 sources stand behind the page.

FieldValueCited text
Known as Afatinib “Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR...” PMID 24439929 ↗ Jan 2014
169

“This is an investigational study. Afatinib is FDA approved and commercially available to be the first treatment for patients with a specific type of NSCLC that has spread. It...” NCT02271906 ↗

“Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice...” PMID 31486833 ↗ Nov 2019

“evaluate the efficacy and safety of XH-30002 capsule in combination with afatinib maleate tablets in patients with locally advanced or metastatic esophageal squamous cell carcinoma” NCT05927844 ↗

“A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations” NCT01647711 ↗

“Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours” NCT00716417 ↗

“A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers.” NCT00875433 ↗

“Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.” NCT00950742 ↗

“Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide.” NCT03623750 ↗

“The MTD was determined as afatinib 30 mg in combination with daily TMZ and RT, and afatinib 40 mg in combination with RT alone.” PMID 34787778 ↗ Nov 2021

“PURPOSE: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.” PMID 30088048 ↗ Aug 2018

Show 159 more sources
Known as Afatinib Dimaleate “Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice...” PMID 31486833 ↗ Nov 2019
1

“Drug: Afatinib Dimaleate” NCT02364609 ↗
Known as BIBW2992 “A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small cell Lung Cancer With...” NCT01090011 ↗
68

“Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation...” NCT00993499 ↗

“An Open Label Expanded Access Program of Afatinib (BIBW 2992) in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung...” NCT01931306 ↗

“LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the...” NCT01271725 ↗

“So far, there is uncertainty, if afatinib (BIBW 2992), an irreversible HER family blocker can lead to an even more complete blockade of the HER2 pathway when given in...” NCT01594177 ↗

“LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small cell Lung Cancer (NSCLC) Harboring...” NCT01649284 ↗

“LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy” NCT01523587 ↗

“LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy” NCT01345669 ↗

“An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours” NCT01206816 ↗

“Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform” NCT00977431 ↗

“A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers.” NCT00875433 ↗

Show 58 more sources
Known as Gilotrif “This phase I/Ib trial will assess the dose, safety and side effects of the combination of the cancer drugs afatinib (GILOTRIF®) and nivolumab (OPDIVO®) and to assess the...” NCT03652233 ↗
3

“will be treated with orally administered daily dose of afatinib (Gilotrif®) in a fasting state (1 hour before or 2 hours after meals).” NCT04533321 ↗

“Afatinib (Gilotrif™) is currently used for metastatic non-small-cell lung cancer with EGFR mutations” PMID 34004576 ↗ May 2021

“Afatinib (GILOTRIF) is a highly potent, irreversible inhibitor of the EGFR and HER2.” NCT02274012 ↗
Action Inhibit “a dual, irreversible EGFR- and HER2-inhibitor” NCT00425854 ↗
Modality Small molecule “Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors - afatinib, erlotinib, icotinib, and gefitinib - are available for first-line treatment of...” PMID 30584317 ↗ Nov 2018
Route Oral “Once Daily Oral Dose” NCT00425854 ↗
Target EGFR “a dual, irreversible EGFR- and HER2-inhibitor” NCT00425854 ↗